Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
14,417 results
- Oncolo-GISTIndependent statistical analysis of Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ondansetron and the QT Interval In Adult Emergency Department Patients: Complete Statistical AnalysisIndependent statistical analysis of Ondansetron and the QT Interval In Adult Emergency Department Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01759420).
- One Touch VerioIQ US Clinical Outcomes Study: Complete Statistical AnalysisIndependent statistical analysis of One Touch VerioIQ US Clinical Outcomes Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01627899).
- One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study: Complete Statistical AnalysisIndependent statistical analysis of One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00580788).
- One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age: Complete Statistical AnalysisIndependent statistical analysis of One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response…
- One Year Study of Rifaximin Delayed Release (DR) in Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- One-Day Acceptance and Commitment Training Intervention in Primary Care Patients: Complete Statistical AnalysisIndependent statistical analysis of One-Day Acceptance and Commitment Training Intervention in Primary Care Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01879800).
- One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens: Complete Statistical AnalysisIndependent statistical analysis of One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology: Complete Statistical AnalysisIndependent statistical analysis of One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Online Caregiver Psychoeducation and Support for Alzheimer’s: Complete Statistical AnalysisIndependent statistical analysis of Online Caregiver Psychoeducation and Support for Alzheimer's: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00416078).
- Online MBCT Program for University Students: Complete Statistical AnalysisIndependent statistical analysis of Online MBCT Program for University Students: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05804877).
- Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers: Complete Statistical AnalysisIndependent statistical analysis of Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan: Complete Statistical AnalysisIndependent statistical analysis of ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ONPEDIndependent statistical analysis of Oral Naltrexone In Pediatric Eating Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05073679).
- onset 9Independent statistical analysis of Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes: primary endpoint results, effect estimate with confidence…
- ONTAKIndependent statistical analysis of A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ONWARDIndependent statistical analysis of A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD): primary endpoint results, effect estimate with confidence interval,…
- ONWARDS 5Independent statistical analysis of A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used…
- ONYXIndependent statistical analysis of Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection: primary endpoint results, effect estimate…
- Onyx ONE ClearIndependent statistical analysis of A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear): primary endpoint results, effect estimate with…
- OPAL BEYONDIndependent statistical analysis of Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OPALINEIndependent statistical analysis of OPALINE : A Study Of Morbidity And Mortality At 2 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known: Complete Statistical AnalysisIndependent statistical analysis of Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known: primary endpoint results, effect estimate with…
- Open Label Crossover Study Pharmacokinetics (PK) Study in Healthy Volunteers Receiving Various Forms of Fentanyl: Complete Statistical AnalysisIndependent statistical analysis of Open Label Crossover Study Pharmacokinetics (PK) Study in Healthy Volunteers Receiving Various Forms of Fentanyl: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel: Complete Statistical AnalysisIndependent statistical analysis of Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02946788).
- Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD): Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD): primary endpoint results, effect estimate with confidence…
- Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia: Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with…
- Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen: Complete Statistical AnalysisIndependent statistical analysis of Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05459688).
- Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): primary endpoint results, effect estimate with confidence interval, sample-size…
- Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study: Complete Statistical AnalysisIndependent statistical analysis of Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study: primary endpoint results, effect estimate with confidence interval,…
- Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: Complete Statistical AnalysisIndependent statistical analysis of Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults: Complete Statistical AnalysisIndependent statistical analysis of Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults: primary endpoint results, effect estimate with…
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02904902).
- Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) – Tuberculosis (TB) Co-infection: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…